ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Neurofibromatosis Type II
Gene/Gene Panel: NF2
Context: Pediatric
Date
Status
Release
Outcomes-Interventions
Notes
2022/02/09
Released
1.0.2
P
Morbidity and mortality from NF2-related tumors (GroupA)
Management in specialty centers with multidisciplinary teams for comprehensive care (includes hearing preservation and augmentation, appropriate surveillance, and downstream management) (GroupA) 10CB
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
NF2 ⇔ 0007039 NEUROFIBROMATOSIS, TYPE II; NF2
Strong Actionability
Strong Actionability
2022/02/09
Released (Under revision)
1.0.1
P
Morbidity and mortality from NF2-related tumors (GroupA)
Management in specialty centers with multidisciplinary teams for comprehensive care (includes hearing preservation and augmentation, appropriate surveillance, and downstream management) (GroupA) 10CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
NF2 ⇔ 0007039 NEUROFIBROMATOSIS, TYPE II; NF2
Strong Actionability
Strong Actionability
2021/05/05
Released
1.0.1
P
Morbidity and mortality from NF2-related tumors (GroupA)
Management in specialty centers with multidisciplinary teams for comprehensive care (includes hearing preservation and augmentation, appropriate surveillance, and downstream management) (GroupA) 10CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
NF2 ⇔ 0007039 NEUROFIBROMATOSIS, TYPE II; NF2
Strong Actionability
Strong Actionability
2021/05/05
Released (Under revision)
1.0.0
P
Morbidity and mortality from NF2-related tumors (GroupA)
Management in specialty centers with multidisciplinary teams for comprehensive care (includes hearing preservation and augmentation, appropriate surveillance, and downstream management) (GroupA) 10CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
NF2 ⇔ 0007039 NEUROFIBROMATOSIS, TYPE II; NF2
Strong Actionability
Strong Actionability
2021/05/05
Released
1.0.0
P
Morbidity and mortality from NF2-related tumors (GroupA)
Management in specialty centers with multidisciplinary teams for comprehensive care (includes hearing preservation and augmentation, appropriate surveillance, and downstream management) (GroupA) 10CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
NF2 ⇔ 0007039 NEUROFIBROMATOSIS, TYPE II; NF2
Strong Actionability
Strong Actionability
2020/02/19
In Preparation
N/A
We have begun assessment of the Pediatric context for this topic
¤ Powered by BCM's Genboree.